COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00074243
Recruitment Status : Completed
First Posted : December 11, 2003
Last Update Posted : April 30, 2015
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as CC-8490, work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of CC-8490 in treating patients who have recurrent or refractory high-grade gliomas.

Condition or disease Intervention/treatment Phase
Brain and Central Nervous System Tumors Drug: CC-8490 Phase 1

Detailed Description:



  • Determine the maximum tolerated dose of CC-8490 in patients with recurrent or refractory high-grade gliomas.
  • Determine, preliminarily, the toxic effects of this drug in these patients.
  • Determine the pharmacokinetics of this drug in these patients.


  • Determine, preliminarily, the potential anti-glioma activity of this drug in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive oral CC-8490 once daily on days 1 and 3-28 (course 1 only). Beginning with course 2 and for all subsequent courses, patients receive oral CC-8490 once daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of CC-8490 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, a total of 10 patients are treated at that dose.

Patients are followed within 2 weeks.

PROJECTED ACCRUAL: A total of 34 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: A Phase I Trial Of CC-8490 For The Treatment Of Patients With Recurrent/Refractory High-Grade Gliomas
Study Start Date : December 2003

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed supratentorial malignant glioma, including any of the following:

    • Glioblastoma multiforme
    • Gliosarcoma
    • Anaplastic astrocytoma
    • Anaplastic oligodendroglioma
    • Anaplastic mixed oligoastrocytoma
    • Malignant glioma/astrocytoma not otherwise specified OR
  • Clinical and radiographic diagnosis of progressive low-grade glioma
  • Radiographically diagnosed infiltrating brain stem gliomas not amenable to biopsy allowed
  • Recurrent or progressive disease as determined by 1 of the following:

    • CT scan or MRI within the past 21 days
    • Biopsy within the past 12 weeks
  • Failed prior radiotherapy



  • 18 and over

Performance status

  • Karnofsky 60-100%

Life expectancy

  • More than 8 weeks


  • Granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3 (transfusion independent)
  • Hemoglobin at least 8 g/dL (transfusion allowed)


  • Bilirubin no greater than 1.5 mg/dL
  • AST and ALT no greater than 2 times upper limit of normal
  • No significant active hepatic disease that would preclude study participation


  • Creatinine no greater than 1.5 mg/dL OR
  • Creatinine clearance at least 60 mL/min
  • No significant active renal disease that would preclude study participation


  • No significant active cardiac disease that would preclude study participation


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 2 months after study participation
  • No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
  • No significant active psychiatric disease that would preclude study participation
  • No other condition or laboratory abnormality that would preclude study participation
  • Able to swallow capsules whole


Biologic therapy

  • At least 2 weeks since prior interferon
  • No concurrent immunotherapy


  • At least 2 weeks since prior vincristine
  • At least 3 weeks since prior procarbazine
  • At least 4 weeks since prior temozolomide or carboplatin
  • At least 6 weeks since prior nitrosoureas
  • No other concurrent anticancer chemotherapy

Endocrine therapy

  • At least 2 weeks since prior tamoxifen
  • Concurrent steroids allowed provided dose has been stable for at least 5 days prior to study enrollment


  • See Disease Characteristics
  • At least 2 weeks since prior radiotherapy
  • No concurrent radiotherapy


  • At least 2 weeks since prior resection of a recurrent or progressive tumor


  • At least 2 weeks since other prior non-cytotoxic therapy
  • At least 4 weeks since other prior cytotoxic therapies
  • More than 28 days since prior experimental study drugs
  • No other concurrent investigational agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00074243

Layout table for location information
United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States, 20892-1182
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Howard A. Fine, MD NCI - Neuro-Oncology Branch

Layout table for additonal information Identifier: NCT00074243    
Obsolete Identifiers: NCT00071864
Other Study ID Numbers: CDR0000343702
First Posted: December 11, 2003    Key Record Dates
Last Update Posted: April 30, 2015
Last Verified: November 2006
Keywords provided by National Cancer Institute (NCI):
adult anaplastic astrocytoma
adult anaplastic oligodendroglioma
adult glioblastoma
adult mixed glioma
adult brain stem glioma
recurrent adult brain tumor
adult giant cell glioblastoma
adult gliosarcoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Nervous System Diseases